Sangamo Therapeutics (SGMO) Misses Q3 EPS by 27c

Sangamo Therapeutics (NASDAQ: SGMO) reported Q3 EPS of ($0.59), $0.27 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $9.39 million versus the consensus estimate of $9.36 million.

For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• Incyte (INCY) Reiterated at Neutral by Cantor Fitzgerald After Management Chat
• Brinker Int'l (EAT) PT Lowered to $240 at DA Davidson Ahead of Analyst Day